PD-L1 Protein (DYKDDDDK Tag)

Catalog No. ABIN2713592

Recombinant PD-L1 protein expressed in Insect cells (Sf9).

Quick Overview for PD-L1 Protein (DYKDDDDK Tag) (ABIN2713592)

Target: PD-L1 (CD274 (PD-L1))

Protein Type: Recombinant

Origin: Human

Source: Insect cells (Sf9)

Application: Antibody Production (AbP), Standard (STD)

Purity: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Product Details

Purification tag / Conjugate: This PD-L1 protein is labelled with DYKDDDDK Tag.

Characteristics:

• Recombinant human CD274 / PDL1 (C-term DDK tag) protein expressed in Sf9 cells.
• Produced with end-sequenced ORF clone

Application Details

Application Notes: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Comment:

The tag is located at the C-terminal.

Restrictions: For Research Use only

Handling

Concentration: 50 μg/mL

Buffer: 50 mM Tris-HCl, pH 8.0, 100 mM glycine, 10 % glycerol.

Storage: -80 °C

Storage Comment: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Target Details

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: Cd274,pdl1

Background: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

Molecular Weight: 31 kDa

NCBI Accession: NP_054862

Pathways: Cancer Immune Checkpoints